Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study On The Impact Of Early Response To First-line Anti-PD-1 Therapy In Patients With Recurrent And/Or Metastatic (R/M) Head And Neck Squamous Cell Carcinoma, Assessed By 18F-FDG PET/CT

NCT07448727 is registered in ClinicalTrials.gov with University of Rome Tor Vergata as lead sponsor.

NCT NCT07448727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07448727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study On The Impact Of Early Response To First-line Anti-PD-1 Therapy In Patients With Recurrent And/Or Metastatic (R/M) Head And Neck Squamous Cell Carcinoma, Assessed By 18F-FDG PET/CT
Lead sponsor
University of Rome Tor Vergata
Phase
Observational
Overall status
Recruiting
Start date
November 20, 2024
Completion date
December 31, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head & neck cancer, head & neck squamous cell carcinoma